Latest Regulatory Filings News

Bannerman Energy reported a substantial $14.17 million cash outflow in its December quarter, driven by aggressive exploration and evaluation investments, leaving the company with $81.1 million in cash reserves.

Stavely Minerals reported a $1.593 million net cash outflow for Q4 2024 but plans to reduce exploration expenditure in the coming quarter to preserve its $2.673 million cash balance.

Energy Action Limited reported a positive net cash inflow from operating activities of $1.076 million for the December quarter, maintaining a solid cash position amid ongoing financing arrangements.

New Murchison Gold Limited reports a significant 39% increase in indicated gold resources at its Crown Prince deposit and secures a strategic ore purchase deal with Westgold, setting the stage for mining to commence mid-2025.

E79 Gold Mines Limited reported a $169,000 net cash outflow from operating activities for the December 2024 quarter, maintaining a solid cash balance of $1.46 million as it continues its exploration efforts.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

Waratah Minerals Limited reported a $2.01 million net cash outflow from operating activities in the December 2024 quarter, ending with $4.23 million in cash and equivalents. The company continues its exploration efforts but faces notable cash burn that may pressure future funding.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Develop Global Limited reported a robust increase in cash reserves for the December 2024 quarter, driven by significant financing inflows despite ongoing operational and investing outflows.

BOSS Energy Limited's December quarter cash flow report reveals a $7.9 million net cash outflow from operations and a slight reduction in cash reserves to $65.2 million, underscoring ongoing investment in exploration activities.

Opthea Limited has spotlighted Sozinibercept as a potential game-changer in wet age-related macular degeneration (AMD) therapy, presenting compelling clinical data and a clear path to U.S. market entry.